Tasmar

Tasmar is a brand name of tolcapone, approved by the FDA in the following formulation(s):

TASMAR (tolcapone - tablet; oral)

• 
  Manufacturer: VALEANT PHARM INTL
  
  Approval date: January 29, 1998
  
  Strength(s): 100MG ^[RLD]

Has a generic version of Tasmar been approved?

No. There is currently no therapeutically equivalent version of Tasmar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tasmar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Catechol derivatives
  Patent 5,236,952
  Issued: August 17, 1993
  Inventor(s): Bernauer; Karl & Borgulya; Janos & Bruderer; Hans & DaPrada; Mose & Zurcher; Gerhard
  Assignee(s): Hoffmann-La Roche Inc.
  Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.
  
  Patent expiration dates:
  
  
  • January 29, 2012
    
  
  



• 
  Catechol derivatives
  Patent 5,476,875
  Issued: December 19, 1995
  Inventor(s): Bernauer; Karl & Borgulya; Janos & Bruderer; Hans & Da Prada; Mose & Zurcher; Gerhard
  Assignee(s): Hoffman-La Roche Inc.
  Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adenosylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuronal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure.
  
  Patent expiration dates:
  
  
  • December 19, 2012
    
    ✓ 
    Patent use: TREATMENT OF PARKINSON'S DISEASE
  
  

See also...

• Tasmar Consumer Information (Wolters Kluwer)
• Tasmar Consumer Information (Cerner Multum)
• Tasmar Advanced Consumer Information (Micromedex)
• Tasmar AHFS DI Monographs (ASHP)
• Tolcapone Consumer Information (Wolters Kluwer)
• Tolcapone Consumer Information (Cerner Multum)
• Tolcapone Advanced Consumer Information (Micromedex)
• Tolcapone AHFS DI Monographs (ASHP)